Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14597962 | 0.86 | SMN1; SMN2 (0.67) | ARSMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL12195177 | 0.84 | AR (0.73) | ARSMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL18155143 | 0.81 | AR (1.00) | ARSMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL14304933 | 0.80 | BCHE (0.77) | ARSMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL5503497 | 0.79 | LMNA (0.85) | ARSMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL9439554 | 0.78 | SMN1; SMN2 (0.71) | ARSMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL11475158 | 0.78 | BCHE (1.00) | ARSMN1; SMN2NPC1LMNAKMT2A | |
| SCHEMBL8501307 | 0.77 | CYP2C9 (0.74) | ARSMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL5114943 | 0.76 | AR (1.00) | ARSMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL29001688 | 0.76 | NPC1 (0.68) | ARSMN1; SMN2NPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | REDPOINT BIO CORPORATION (US) | 2010-08-05 | — | — | US | claimed |
| US-7674831-B2 | Heterocyclic compounds as sweetener enhancers | REDPOINT BIO CORPORATION (US) | 2010-03-09 | — | — | US | claimed |
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION | 2008-10-09 | — | — | US | claimed |
| EP-1784182-A1 | 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | claimed |
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ALLA CHEM, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ALLA CHEM, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | REDPOINT BIO CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | REDPOINT BIO CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | REDPOINT BIO CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010074607-A2 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | АЛЛА XEM, ЛЛС (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7674831-B2 | Heterocyclic compounds as sweetener enhancers | REDPOINT BIO CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674831-B2 | Heterocyclic compounds as sweetener enhancers | REDPOINT BIO CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674831-B2 | Heterocyclic compounds as sweetener enhancers | REDPOINT BIO CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2061321-A2 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | Redpoint Bio Corporation (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2008024364-A2 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024364-A2 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | REDPOINT BIO CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249189-A1 | HETEROCYCLIC COMPOUNDS AS SWEETENER ENHANCERS | TAS2R1, TAS1R1, TAS2R40 | AR 3514/4885SMN1; SMN2 1710/4885NPC1 3113/4885 |
| US-20100197813-A1 | Heterocyclic Compounds as Sweetener Enhancers | TAS2R1, TAS1R1, TAS2R40 | AR 3514/4885SMN1; SMN2 1710/4885NPC1 3113/4885 |
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ADH1C, ADH1A, ADH5 | AR 1279/4885SMN1; SMN2 3094/4885NPC1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.